Previous studies have reported on aberrant activation of various cellular pathways such as GSK-3 beta-C/EBP alpha-miR-122-Insulin Growth Factor 1 Receptor [11], HDGF-related protein-3 [12], FoxM1/ACP5 [13], JAK/STAT [14], miR-219-5p/glypican-3 [15] etc. Moreover, recent studies have demonstrated the importance of the JAK/STAT pathway in the development of HCC, and suggest that the use of JAK/STAT inhibitors might have potential in the treatment of HCC [16]. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.